Preperitoneal fat deposition estimated by ultrasonography in patients with non-insulin-dependent diabetes mellitus.
Preperitoneal fat is an indicator of visceral fat deposition, which is closely related to atherosclerosis and coronary heart disease in obese patients. We assessed the relationship of preperitoneal fat deposition and various clinical characteristics in 90 patients with non-insulin-dependent diabetes mellitus (NIDDM). Preperitoneal and subcutaneous fat deposition were measured by ultrasonography. In both the male and female diabetics, preperitoneal fat levels were significantly higher than in age-matched healthy subjects. We also determined blood pressures, fasting plasma glucose, glycosylated hemoglobin A1c, serum lipids, fasting immunoreactive insulin (FIRI), daily urinary C-peptide (CPR), serum leptin, urinary albumin excretion and body mass index (BMI). Of these parameters, BMI, FIRI, leptin and daily urinary CPR were positively correlated with preperitoneal fat deposition. Patients with diet therapy alone showed significantly higher preperitoneal fat levels than those receiving insulin therapy. In female, patients with increased preperitoneal fat showed higher prevalence of hypertension than those with decreased fat. Macroalbuminuric patients had a lower preperitoneal fat than microalbuminuric and normoalbuminuric patients. Patients with proliferative retinopathy exhibited lower preperitoneal fat than did those without retinopathy. Preperitoneal fat levels were positively correlated with motor or sensory nerve conduction velocity.


CONCLUSIONS
The present findings suggest that in NIDDM patients, increased preperitoneal fat deposition is closely associated with obesity, hypertension and hyperinsulinemia, and negatively modulates diabetic microangiopathy including nephropathy, retinopathy and neuropathy.
Tayama
K
K
Department of Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, Japan.
Inukai
T
T
Shimomura
Y
Y
D000273:Adipose Tissue / Q000000981:diagnostic imaging*; D000419:Albuminuria / Q000652:urine; D015992:Body Mass Index; D002096:C-Peptide / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000000981:diagnostic imaging* / Q000178:diet therapy / Q000188:drug therapy / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000000981:diagnostic imaging; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D020738:Leptin; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000502:physiology; D010537:Peritoneum / Q000000981:diagnostic imaging*; D011506:Proteins / Q000032:analysis; D012016:Reference Values; D012677:Sensation / Q000502:physiology; D012867:Skin / Q000000981:diagnostic imaging; D013997:Time Factors; D014463:Ultrasonography
D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin; D020738:Leptin; D011506:Proteins